Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharmacia Somavert Clears FDA For Acromegaly; Liver Testing Recommended

Executive Summary

Labeling for Pharmacia's acromegaly treatment Somavert recommends monthly liver function monitoring for the first six months of treatment

You may also be interested in...

Novartis Ups Ante In Acromegaly Injectables As Oral Contender Emerges

Novartis gears up to file new injectable pasireotide LAR by the end of 2012 for the niche acromegaly market, ahead of the patent expiration of its blockbuster Sandostatin LAR. But Israeli biotech Chiasma is hoping to deliver an oral option with Octreolin.

Emend Risk Program To Ensure Prescribers Understand Approved Indication

Merck's risk management program for Emend will emphasize the anti-emetic's approved indication to deter prescribing for non-approved indications

Pharmacia Somavert Manufacturing Changes Planned For U.S. Approval

Pharmacia expects FDA approval of the acromegaly drug Somavert (pegvisomant) in the "next several months" pending clearance of a revised manufacturing process

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts